Company
Headquarters: Beijing, China
Employees: 3,592
CN¥32.94 Billion
CNY as of Jan. 1, 2026
US$4.70 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥6.42 B |
| EBITDA | CN¥2.50 B |
| Gross Profit TTM | CN¥3.00 B |
| Profit Margin | 20.49% |
| Operating Margin | 24.21% |
| Quarterly Revenue Growth | 10.00% |
Beijing Tiantan Biological Products Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600161 wb_incandescent